• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » The CenterWatch Monthly, August 2011

The CenterWatch Monthly, August 2011

August 1, 2011
CenterWatch Staff

Sponsors target new areas to speed cycle times

Biopharmaceutical company executives struggle to find ways of shortening drug development cycle time. Sponsors place a high priority on accelerating cycle time to help improve R&D productivity, yet median cycle times, according to analysis of FDA and industry data, increased by nearly 15% between 1994 and 2009, from 77.3 to 81.9 months. Executives say the greatest challenge to reducing cycle time is the large, phase III clinical trial, which has become more complex. Yet overall, these executives say the most promising areas for improving cycle times are...

Anticipating new clinical trials business for biosimilars

Pharmaceutical companies that once scoffed at generics are getting ready to enter a new business: making copycat version of expensive biotechnology drugs, often with required clinical trials, to fill their dwindling drug pipelines. And they are not alone, as biotech companies are also pursuing the fledgling biosimilar market that has sprouted in Europe. Now there are early signs of an FDA regulatory pathway specifically for biosimilar development...

Eye On Novo Nordisk

Novo Nordisk, a global healthcare company headquartered in Denmark, opened in 1923. In addition to pursuing pharmacotherapy for diabetes and other Endocrinology indications, Novo Nordisk is in active development of drug candidates in Hematology and Inflammation...

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing